Pharmaceutical giant Pfizer has made an offer worth approximately $100 million to buy 100 per cent of the shares in AXS-listed respiratory health software developer ResApp Health.

ResApp and Pfizer have also entered into a research and development license agreement to work together on R&D for products in the field of COVID-19. ResApp recently announced it was planning a randomised control trial of its new app-based diagnostic screening tool for COVID-19.